First biomarker-based chemical allergy test launched
GARDair removes the need for animal testing and opens a completely new market.
SenzaGen will launch GARDair, the first in vitro test for airway allergies at ESTIV2018, the 20th International Congress on In Vitro Toxicology. Removing the need for animal testing and opening a completely new market, GARDair is based on the company’s proprietary GARD technology platform. Using genetic biomarkers, GARDair tests whether substances and chemicals that are inhaled or come into contact with the lungs are allergenic or not, with high accuracy.
Respiratory allergies or respiratory sensitization, which manifests itself primarily in the form of asthma, is a growing problem. About 8-10% of the Swedish population suffer from asthma and more than 300 million people worldwide are diagnosed with asthma - a figure that is expected to increase in the next few years. There are currently no methods available for testing whether chemicals can contribute to or cause allergic reactions in the respiratory tract.
GARDair makes use of genetic biomarkers which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity with high accuracy. GARDair is targeted primarily at the chemical, pharmaceutical and cosmetic industries where there are a wide range of testing needs from pesticides to fragrances. GARDair will be marketed through SenzaGen's laboratory in Lund and the company's licensing laboratories, which will allow immediate availability in Europe and the US.
Using the same technology platform as the already launched GARDskin, GARDair is supported by the EU's SME program Horizon2020 and has been developed in co-operation with AstraZeneca.
“I have been advising SenzaGen in their preparations for the commercialization of GARDair in my capacity as external and independent Horizon2020 coach. SenzaGen is for me a true EU success story and meets the aims of Horizon2020 by translating an excellent technology platform into a number of excellent products and offerings for the market. It is a true ’High-Tech’ business. They have unique products in growth markets and excellent management. I believe that GARDair will contribute to making SenzaGen a very profitable and successful company,” said Paul Yianni, Horizon2020 coach.
"There is a huge demand for GARDair from customers in the chemicals, pharmaceutical and cosmetics industries. The ability to test without using animal models whether substances might cause airway allergies brings major benefits in several ways – not only when it comes to developing better and safer products, but also by offering employees a safe production and working environment. GARDair in combination with GARDskin provides new insights and thereby new opportunities for our customers to actively avoid chemicals with multiple allergenic effects," says Anki Malmborg Hager, CEO of SenzaGen.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News Pharmapack 2024 - From the Floor
Paris once again welcomes Europe’s leading trade show in pharmaceutical packaging and drug delivery innovation. Join our content team as Pharmapack 2024 opens its doors to leading experts and innovators in pharmaceutical packaging and drug delive... -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most. -
News CPHI Barcelona 2023: Loading Potential – Artificial Intelligence for Pharma Manufacturing
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most. -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News CPHI Podcast Series: Start-ups take centre stage at CPHI Barcelona
The first episode of the CPHI Podcast Series since we attended CPHI Barcelona in October covers the Start-up market at the event, with expert Matthew Wise joining Editor Lucy Chard to discuss the event.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance